Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
AD patients with mutant allele (*10) in CYP2D6 gene may respond better to donepezil than those with wild allele (*1).
|
22986607 |
2013 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease.
|
10208640 |
1999 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease.
|
16909003 |
2005 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CYP2D6*10 carriers responded better to ChEIs and resulted in better improvement in Alzheimer's Disease Assessment Scale-Cognitive subscale (<i>P</i> = .027) and Mini-Mental State Examination (<i>P</i> = .012).
|
31064198 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
About 57.76% of patients with Alzheimer's disease are extensive metabolisers (EMs) for CYP2D6 enzymes, 31.06% are intermediate metabolisers (IMs), 5.28% are poor metabolisers (PMs), and 5.90% are ultrarapid metabolisers (UMs); 73.71% are CYP2C19-EMs, 25.12% IMs, and 1.16% PMs; 60.87% are CYP2C9-EMs, 34.16% IMs, and 4.97% PMs; 82.75% are CYP3A4/5-EMs, 15.88% IMs, and 1.37% UMs.
|
20197699 |
2010 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Also, due to such a rare occurrence of the CYP2D6*4 polymorphism, we can not confirm the protective role of the polymorphism against AD in the Korean population.
|
11442888 |
2001 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analyses of the cytochrome P450 CYP2D6-debrisoquine 4-hydroxylase mutant B allele, a susceptibility gene for PD, revealed a higher representation of this allele in the Lewy body variant of AD than in pure AD or non-AD without Lewy bodies.
|
7818242 |
1995 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
|
21630031 |
2011 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Behavioral symptoms, sex, or genetic factors, including Beta 2-adrenergic receptor variants, apolipoprotein E, and cytochrome P450 CYP2D6, may contribute to beta-adrenergic receptor blockade modulation in AD.
|
23689075 |
2013 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both univariate and multiple linear regression analysis indicated that only <i>CYP2D6*10</i> allele was associated with higher Cpss (<i>p</i>-value =0.029 and B =0.478, <i>p</i>-value =0.032, respectively) that might influence the clinical outcomes of donepezil. ie, TMSE (<i>p</i>-value =0.010 and B =4.527, <i>p</i>-value =0.001) and ΔTMSE (<i>p</i>-value =0.023 and B =4.107, <i>p</i>-value =0.002), especially in patients with AD.
|
31564952 |
2019 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.
|
24107805 |
2014 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
In AD patients treated with a multifactorial therapy, including cholinesterase inhibitors (e.g., donepezil), the best responders are the CYP2D6-related EMs and IMs, and the worst responders are PMs and UMs.
|
17908053 |
2007 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, about 10-20% of Caucasians are carriers of defective CYP2D6 polymorphic variants that alter the metabolism and effects of AD drugs and many psychotropic agents currently administered to patients with dementia.
|
18322383 |
2008 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In order to elucidate whether a relationship exists between CYP2D6 polymorphism and the risk of developing Alzheimer's disease (AD), CYP2D6 allele and genotype frequencies have been evaluated in 94 patients from Southern Italy (29 men and 65 women, aged 74+/-8 years) with AD, and in 350 healthy controls (204 men, 146 women, aged 33+/-9 years) from the same geographical region.
|
16337409 |
2006 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In total, 15% of the Caucasian population with Alzheimer's disease are carriers of defective CYP2D6 polymorphic variants that are potentially responsible for therapeutic failures when receiving cholinesterase inhibitors and psychotropic drugs.
|
16197352 |
2005 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It remains controversial whether, and to what extent, individual variation in the genes responsible for drug metabolism (CYP2D6) or those associated with AD pathogenesis (APOE) modulate the response to donepezil treatment.
|
27282366 |
2016 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.
|
17908053 |
2007 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Pharmacogenomics studies also indicate that the therapeutic response in AD is genotype-specific and that approximately 15% of the cases with efficacy and/or safety problems are associated with a defective CYP2D6 gene.
|
12943467 |
2003 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The AD susceptibility gene cholesterol 25-hydroxylase (<i>CH25H</i>) is upregulated in the AD brain and is involved in the antiviral immune response.
|
29559905 |
2018 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to examine the genetic polymorphism in cytochrome P450 2D6 (CYP2D6) and glutathione S-transferases pi 1 (GSTP1) with respect to organochlorine pesticides (OCPs) and metals in AD.
|
24584466 |
2014 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate the effect of 16 functional polymorphisms in the CYP2D6 gene on the clinical response to donepezil treatment in patients with mild-to-moderate AD.
|
20859244 |
2011 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The analysis of CYP2D6 genotypes may be useful in identifying subgroups of patients with AD who have different clinical responses to donepezil.
|
19738170 |
2009 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease.
|
7574463 |
1995 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There is a moderate accumulation of AD-related genetic variants of risk in CYP2D6 poor metabolizers (PMs) and ultrarapid metabolizers (UMs), who are the worst responders to conventional drugs.
|
18370236 |
2008 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was no relationship between CYP2D6 alleles and the age of onset and advancement of dementia in AD and PD.
|
17530572 |
2007 |